Apogee Therapeutics (APGE) Tax Provisions (2024 - 2026)
Apogee Therapeutics (APGE) posted quarterly Tax Provisions of $79000.0 for Q1 2026, down 4.82% year-over-year from $83000.0 in Q1 2025, and up 100.15% quarter-over-quarter from -$53.9 million in Q4 2025.
Apogee Therapeutics (APGE) Tax Provisions (2024 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Tax Provisions for 3 consecutive years, with $79000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 4.82% year-over-year to $79000.0; the TTM figure through Mar 2026 stood at -$53.7 million (down 11593.46% YoY), while the FY2025 annual figure was -$53.7 million, down 9802.03% from the prior year.
- Tax Provisions rose to $79000.0 in Q1 2026 per APGE's latest filing, from -$53.9 million in the prior quarter.
- Across five years, Tax Provisions topped out at $83000.0 in Q1 2025 and bottomed at -$53.9 million in Q4 2025.
- Historically, Tax Provisions has averaged -$9.0 million across 3 years, with a median of $66500.0 in 2025.
- Annual changes were most pronounced in 2025 — Tax Provisions plunged 9841.88% — and 2026, when it dropped 4.82%.
- Apogee Therapeutics' Tax Provisions stood at -$542000.0 in 2024, then slumped by 9841.88% to -$53.9 million in 2025, then surged by 100.15% to $79000.0 in 2026.
- Business Quant data shows APGE's Tax Provisions at $79000.0 in Q1 2026, -$53.9 million in Q4 2025, and $61000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78,000.00 |
| Mar 31, 2026 | 79,000.00 |
| Dec 31, 2025 | -53.89 Mn |
| Sep 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 72,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | -542,000.00 |